Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension

Şengül, Ahmet M.; Altuntaş, Yüksel; Kurklu, A.; Aydın, Levent

doi:10.1016/j.diabres.2005.06.010

Cited by 62 publications

(28 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[39] Similarly, in 219 patients with type 2 diabetes and microalbuminuria, after receiving lisinopril or telmisartan (AT 1 blocker) for six months followed by continuing monotherapy or a combination of the two agents for a further six months, significant declines in albumin excretion rates were observed with lisinopril monotherapy (37.1%; p < 0.001) and telmisartan monotherapy (31.3%; p < 0.001) compared with baseline. [40] Additional significant reductions in albumin excretion rates were seen with combination therapy with lisinopril and telmisartan compared with baseline (52.7% to 53.6%; p < 0.001). [40] Finally, the combination treatment of ang II receptor blocker and ACE inhibitor in a nondiabetic renal disease study of 336 patients found that the combination of losartan (AT 1 blocker) and trandolapril (ACE inhibitor) 3 mg/day increased renal survival significantly more than either monotherapy.…”

Section: Discussionmentioning

confidence: 82%

“…[40] Additional significant reductions in albumin excretion rates were seen with combination therapy with lisinopril and telmisartan compared with baseline (52.7% to 53.6%; p < 0.001). [40] Finally, the combination treatment of ang II receptor blocker and ACE inhibitor in a nondiabetic renal disease study of 336 patients found that the combination of losartan (AT 1 blocker) and trandolapril (ACE inhibitor) 3 mg/day increased renal survival significantly more than either monotherapy. [41] After three years, the combined endpoint of doubling of serum creatinine concentration and endstage renal disease was achieved in 11% of patients receiving combination therapy vs. 23% in either of the monotherapy groups.…”

Section: Discussionmentioning

confidence: 82%

See 1 more Smart Citation

Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Type 1 Receptor Blockade on Streptozotocin-Induced Diabetic Nephropathy

et al. 2008

View full text Add to dashboard Cite

The aim of this study was designed to investigate the possible beneficial effects of the angiotensin-converting enzyme (ACE) inhibitor, Quinapril (Q) and, the angiotensin (ang) II T 1 (AT1) receptor blocker, irbesartan (Irb), in streptozotocin (STZ)-induced diabetes in rats. The rats were randomly allotted into one of five experimental groups: A (control), B (diabetic untreated), C (diabetic treated with Q), D (diabetic treated with Irb), and E (diabetic treated with Q&Irb), each group containing 10 animals. Groups B-E received STZ. Diabetes was induced in four groups by a single intraperitoneal (i.p) injection of STZ (50 mg/kg, freshly dissolved in 5 mmol/L citrate buffer, pH 4.5). Two days after STZ treatment, development of diabetes in four experimental groups was confirmed by measuring blood glucose levels in a tail vein blood samples. Rats with blood glucose levels of 250 mg/dL or higher were considered to be diabetic. The rats in Q-, Irb-, and Q&Irb-treated groups were given Q (in a dose of 3 mg/kg body weight), Irb (5 mg/kg body weight), and Q&Irb (in a dose of 1.5 mg/kg + 2.5 mg/kg body weight) once a day orally by using intra-gastric intubation for 12 weeks starting two days after STZ injection. Treatment of Q and especially Irb reduced the glomerular size and thickening of capsular, glomerular, and tubular basement membranes; and increased amounts of mesangial matrix and tubular dilatation and renal function as compared with diabetics untreated. Notably, the better effects were obtained when Q and Irb given together. We conclude that Q, Irb, and especially Q+Irb therapy causes renal morphologic and functional improvement after STZ-induced diabetes in rats. We believe that further preclinical research into the utility of Q and Irb treatment, alone or its combination, may indicate its usefulness as a potential treatment in diabetic nephropathy (DNp).

show abstract

Section: Discussionmentioning

confidence: 82%

Section: Discussionmentioning

confidence: 82%

Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Type 1 Receptor Blockade on Streptozotocin-Induced Diabetic Nephropathy

et al. 2008

View full text Add to dashboard Cite

show abstract

“…6,[33][34][35] There was no statistical difference in DBP reduction and therapeutic response rate of DBP between the two groups. There was a greater SBP reduction that favored lisinopril.…”

Section: Telmisartan Versus Lisinoprilmentioning

confidence: 81%

Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials

Zou

Yuan

et al. 2008

J Hum Hypertens

View full text Add to dashboard Cite

Telmisartan and angiotensin-converting enzyme inhibitors (ACEIs) are both effective and widely used antihypertensive drugs targeting renin-angiotensinaldosterone system. The study aimed to estimate the efficacy and tolerability of telmisartan in comparison with different ACEIs as monotherapy in the treatment of hypertension. Cochrane Central Register of Controlled Trials, PubMed and Embase were searched for relevant studies. A meta-analysis of all randomized controlled trials fulfilling the predefined criteria was performed. A random-effect model was used to account for heterogeneity among trials. Twenty-eight randomized controlled trials involving 5157 patients were ultimately identified out of 721 studies. Telmisartan had a greater diastolic blood pressure (DBP) reduction than enalapril (weighted mean difference (WMD) 1.82, 95% confidence interval (CI) 0.66-2.99), ramipril (WMD 3.09, 95% CI 1.94-4.25) and perindopril (WMD 1.48, 95% CI 0.33-2.62). Telmisartan also showed a greater DBP response rate than enalapril (relative risk (RR) 1.15, 95% CI 1.05-1.26), ramipril (RR 1.34, 95% CI 1.11-1.61) and perindopril (RR 1.22, 95% CI 1.05-1.41). There was no statistical difference in DBP reduction or therapeutic response rate between telmisartan and lisinopril (WMD À0.30, 95% CI À0.65 to 0.05; RR 0.99, 95% CI 0.80-1.23, respectively). Telmisartan had fewer drug-related adverse events than enalapril (RR 0.57, 95% CI 0.44-0.74), ramipril (RR 0.44, 95% CI 0.26-0.75), lisinopril (RR 0.70, 95% CI 0.56-0.89) and perindopril (RR 0.52, 95% CI 0.28-0.98). The meta-analysis indicates that telmisartan provides a superior BP control to ACEIs (enalapril, ramipril and perindopril) and has fewer drug-related adverse events and better tolerability in hypertensive patients.

show abstract

“…Nevertheless ONTARGET was not designed as a hypertension intervention study 23,24 and it has been shown, that a combination of ARB and ACE inhibitors leeds to an additional BP reduction compared with an ARB or ACE inhibitor application alone. 25,26 However, the BP reduction was more pronounced in the TBPM group due to a faster up-titration of the irbesartan dosage. Furthermore, more patients in the TBPM group (54 vs 34%) achieved the desired 24-h ABPM BP target within 3 months.…”

Section: Discussionmentioning

confidence: 96%

Blood pressure telemonitoring is useful to achieve blood pressure control in inadequately treated patients with arterial hypertension

et al. 2011

View full text Add to dashboard Cite

Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension

Cited by 62 publications

References 33 publications

Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Type 1 Receptor Blockade on Streptozotocin-Induced Diabetic Nephropathy

Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Type 1 Receptor Blockade on Streptozotocin-Induced Diabetic Nephropathy

Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials

Blood pressure telemonitoring is useful to achieve blood pressure control in inadequately treated patients with arterial hypertension

Contact Info

Product

Resources

About